-
公开(公告)号:US12059450B2
公开(公告)日:2024-08-13
申请号:US17281808
申请日:2019-10-02
Applicant: Korea University Research And Business Foundation , CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventor: Min-Jeong Shin , Hyeon Soo Kim , Inhyeok Jeong , Eun Hye Yoo , Ji Hyung Chung
CPC classification number: A61K38/1709 , A23L33/17 , A61P35/00
Abstract: The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.
-
152.
公开(公告)号:US12059257B2
公开(公告)日:2024-08-13
申请号:US17038573
申请日:2020-09-30
Applicant: HYUNDAI MOTOR COMPANY , KIA MOTORS CORPORATION , SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventor: Jeong Su Kang , Suh Yeon Dong
CPC classification number: A61B5/18 , A61B5/165 , A61B5/369 , A61B5/7221 , B60W30/00 , B60W40/08 , B60W2040/0872 , B60W2420/403 , B60W2520/00 , B60W2540/22 , B60W2540/221 , G06V20/597
Abstract: Disclosed herein is an apparatus and method for generating a driving model. The driving model generation method includes sensing to collect a brain wave signal for a driver in a mobility for a predetermined time, determining the driver's state by analyzing the brain wave signal collected for the predetermined time, detecting at least one of operational information and driving information of the mobility on the basis of the determined state of the driver, and storing the detected information. Herein, the brain wave signal includes an event-related potential (ERP), and the determining includes determining, by analyzing the ERP, whether or not the driver is in an unstable state.
-
153.
公开(公告)号:US20240265587A1
公开(公告)日:2024-08-08
申请号:US18422534
申请日:2024-01-25
Inventor: Bum Shik LEE , Muhammad Hamza SHAFIQ
IPC: G06T11/00
CPC classification number: G06T11/001
Abstract: In accordance with various embodiments, an electronic device for colorizing a black and white image using a Generative Adversarial Network (GAN)-based model comprising a transformer block includes a processor, wherein the processor is set to: obtain a black and white image including only first information about a luminance channel; and generate a pseudo color image including only second information about a chrominance channel by applying the black and white image to the GAN-based model, the GAN-based model includes a generator network including a plurality of transformer blocks for color conversion, a plurality of convolution layers, and a plurality of transpose convolution layers, the plurality of transformer blocks each include a Depth Wise Convolution (DWC) layer, a first Layer Normalization (LN) layer, a Window-based Multi-head Self Attention (W-MSA) layer, a second LN layer, and a Colorization Feed Forward (CFF) block. Other various embodiments are possible.
-
154.
公开(公告)号:US20240261734A1
公开(公告)日:2024-08-08
申请号:US18565354
申请日:2022-05-31
Inventor: Kwang Ho CHOO , Syed Salman Ali SHAH
CPC classification number: B01D65/08 , B01D67/00931 , B01D67/00933 , B01D69/02 , C02F1/44 , C02F3/1268 , C02F3/34 , B01D2321/28 , B01D2323/02 , B01D2323/12 , B01D2323/30 , B01D2325/20 , B01D2325/36
Abstract: The present disclosure relates to a membrane filter for water and wastewater treatment including a membrane filter, hydrophilic polymers formed on the membrane filter; and quorum quenching microorganisms cross-linked with the membrane filter by the hydrophilic polymer. The quorum quenching microorganisms are attached to the surface of the membrane filter for water and wastewater treatment, resulting in a higher initial permeation pressure than a conventional membrane, but the quorum quenching microorganisms may effectively prevent the phenomenon of quorum sensing, allowing the formation of a biofilm, thereby improving the life of the membrane filter for water and wastewater treatment.
-
公开(公告)号:US12054524B2
公开(公告)日:2024-08-06
申请号:US17692508
申请日:2022-03-11
Inventor: Kwang Hoon Kong , Han Seul Kim , Si Wook Jang , Gi Hyeon Chae
IPC: C07K14/425 , C12N15/81
CPC classification number: C07K14/425 , C12N15/81 , C12N2800/102 , C12N2830/002 , C12N2830/704
Abstract: The present inventors confirmed that when a brazzein expression recombinant vector for high expression of brazzein in Saccharomyces cerevisiae was prepared and a S. cerevisiae strain Y2805 was transformed with the recombinant vector, the expression level of brazzein was particularly high, thereby completing an optimal expression system for mass-producing brazzein. Further, when the brazzein expression system is cultured under the optimal culture conditions according to the present invention, the amount of brazzein produced is further increased, the purification process is simple, and costs are reduced. Therefore, it is expected that the brazzein expression system according to the present invention can be widely used for mass-producing and commercializing brazzein, which is a sweet protein.
-
156.
公开(公告)号:US20240252547A1
公开(公告)日:2024-08-01
申请号:US18564485
申请日:2022-05-26
Inventor: Jihwan SONG
IPC: A61K35/30 , A61P9/10 , C12N5/0797
CPC classification number: A61K35/30 , A61P9/10 , C12N5/0623 , C12N2500/32 , C12N2500/38 , C12N2500/98 , C12N2501/115 , C12N2506/45 , C12N2533/52
Abstract: A pharmaceutical composition for preventing or treating a stroke, the pharmaceutical composition comprising, as an active ingredient, neural precursor cells differentiated from HLA homozygous human induced pluripotent stem cells (hiPSC-NPC), wherein, through the use of a homozygous type, immunorejection may be eliminated and stable therapeutic effects for stroke may be exhibited.
-
157.
公开(公告)号:US20240252106A1
公开(公告)日:2024-08-01
申请号:US18406418
申请日:2024-01-08
Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION , UNIVERSITY OF SEOUL INDUSTRY COOPERATION FOUNDATION
Inventor: Seung Ho YANG , Young Il KIM , Ha Jin YU
CPC classification number: A61B5/4803 , A61B5/0042 , A61B5/055 , A61B5/4064 , A61B5/7267 , G10L15/063 , G10L15/18 , G10L25/66 , A61B2576/026 , G10L13/02
Abstract: Disclosed is a language area invasion determination apparatus including a memory unit including a language area invasion determination model, and a processor that controls an operation of the language area invasion determination model included in the memory unit. The processor trains the language area invasion determination model by using one or more training utterance data and outputs language area invasion determination data of an examiner by using test utterance data and the trained language area invasion determination model. The training utterance data and the test utterance data include utterance speech data of a speaker.
-
公开(公告)号:US12048927B2
公开(公告)日:2024-07-30
申请号:US18312558
申请日:2023-05-04
Inventor: Ki-Ho Han , Hyung-Seok Cho
CPC classification number: B01L3/502707 , B01L3/502753 , B01L2200/0684 , B01L2300/0816 , B01L2300/0887 , G01N2001/4016
Abstract: Provided is a method for bonding panel of a microfluidic element by using a releasing film including preparing a panel having a pattern for a microfluidic channel formed on one surface thereof, preparing a release film coated with silicon nanoparticles on one or both surfaces thereof, plasma-treating one surface of the panel on which the pattern for the microfluidic channel is formed and the surface of the release film, and bonding the panel and the release film by performing heat treatment at a predetermined temperature range in a state in which the plasma-treated panel and the release film are attached to each other.
-
公开(公告)号:US12048771B2
公开(公告)日:2024-07-30
申请号:US17283480
申请日:2019-10-04
Inventor: Hyungil Jung , Huisuk Yang
CPC classification number: A61K9/7092 , A61M5/422 , A61M37/0015 , A61K9/0021 , A61M2037/0023 , A61M2202/048
Abstract: A multifunctional microstructure patch is provided. The multifunctional microstructure patch, according to one embodiment of the present invention, comprises: a base layer having an opening part formed in the center thereof; a plurality of microstructures formed on one surface of the base layer and comprising a first drug; and a cover layer detachably bonded on the other surface of the base layer along the periphery of the opening part, and formed so as to cover the opening part.
-
160.
公开(公告)号:US20240238343A1
公开(公告)日:2024-07-18
申请号:US18004562
申请日:2021-07-01
Inventor: Sung Won KIM , Do Hyun KIM , Jung Yeon LIM , Sun Hwa PARK , Jung Ho CHUN , Sin-Soo JEUN , Soon A PARK
CPC classification number: A61K35/28 , A61K9/0019 , A61K9/0043 , A61K9/0085 , A61K9/12 , A61P25/28
Abstract: The present invention relates to a pharmaceutical composition comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient, the composition being administered by intranasal or intramaxillary administration by means of olfactory mucosa subepithelial injection, and the like, in order to bypass the blood-brain barrier through a peri-olfactory pathway. The present invention relates to a method in which stem cells, and the like are injected intranasally, thereby enabling various therapeutic materials including the stem cells to be efficiently delivered to the brain and nervous system through the olfactory organ and a trigeminal nervous system pathway, and thus, through the method, it was confirmed that side effects occurring as a result of an entire body being exposed to a drug may be reduced, and further, a sufficient amount of inferior turbinate-derived mesenchymal stem cells may be obtained safely at a desired time at low cost with high efficiency, and it was confirmed that since the composition shares the same genetic origin with the composition-administered subject, the composition exhibits an excellent effect which is the same as or greater than the effects of bone marrow-derived mesenchymal stem cells or adipose-derived mesenchymal stem cells with fewer side effects, and thus, by intranasally administering various therapeutic materials including the nasal inferior turbinate-derived mesenchymal stem cells, the composition is expected to be capable of minimizing side effects and utilized for preventing or developing a treatment for brain and nervous system diseases.
-
-
-
-
-
-
-
-
-